SAFETY DATA SHEET
According to 13 December 2014, No:29204, "Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I".

Montelukast Tablet Formulation

Version 3.0  Revision Date: 09.04.2021  SDS Number: 2097351-00006  Date of last issue: 02.10.2020
Date of first issue: 18.10.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Montelukast Tablet Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company: Organon & Co.
30 Hudson Street, 33nd floor
07302 Jersey City, New Jersey, U.S.A

Telephone: 551-430-6000
E-mail address of person responsible for the SDS: EHSSTEWARD@organon.com

1.4 Emergency telephone number
215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification T.R. SEA No 28848
Not a hazardous substance or mixture.

2.2 Label elements
Labelling T.R. SEA No 28848
Not a hazardous substance or mixture.

Additional Labelling:
EUH210 Safety data sheet available on request.

2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.
SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Montelukast</td>
<td>151767-02-1</td>
<td></td>
<td></td>
<td></td>
<td>Eye Irrit. 2; H319</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td>Substances with a workplace exposure limit:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td></td>
<td></td>
<td></td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Montelukast Tablet Formulation

Version 3.0  Revision Date: 09.04.2021  SDS Number: 2097351-00006  Date of last issue: 02.10.2020  Date of first issue: 18.10.2017

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
SAFETY DATA SHEET
According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”.

Montelukast Tablet Formulation

Version 3.0  Revision Date: 09.04.2021  SDS Number: 2097351-00006  Date of last issue: 02.10.2020  Date of first issue: 18.10.2017

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>ZOAD/TWA (Total dust)</td>
<td>15 mg/m³</td>
<td>TR OEL DU</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: Allowable occupational exposure limit values of chemicals in dust form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montelukast</td>
<td>151767-02-1</td>
<td>TWA</td>
<td>40 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>400 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment
Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material: Chemical-resistant gloves
Montelukast Tablet Formulation

Version 3.0  Revision Date: 09.04.2021  SDS Number: 2097351-00006  Date of last issue: 02.10.2020
Date of first issue: 18.10.2017

Remarks: Consider double gloving.
Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to TS EN 143
Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

- **Appearance**: tablet
- **Colour**: coloured
- **Odour**: odourless
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: Not applicable
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapour pressure**: No data available
- **Relative vapour density**: No data available
- **Relative density**: No data available
- **Density**: No data available
- **Solubility(ies)**
  - **Water solubility**: No data available
SAFETY DATA SHEET
According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”.

Montelukast Tablet Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue: 02.10.2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.0</td>
<td>09.04.2021</td>
<td>2097351-00006</td>
<td>Date of first issue: 18.10.2017</td>
</tr>
</tbody>
</table>

- Partition coefficient: n-octanol/water: No data available
- Auto-ignition temperature: No data available
- Decomposition temperature: No data available
- Viscosity
  - Viscosity, kinematic: No data available
- Explosive properties: Not explosive
- Oxidizing properties: The substance or mixture is not classified as oxidizing.

9.2 Other information
- Flammability (liquids): No data available
- Molecular weight: No data available
- Particle size: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
- Not classified as a reactivity hazard.

10.2 Chemical stability
- Stable under normal conditions.

10.3 Possibility of hazardous reactions
- Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
- Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
- Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
- No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
- Information on likely routes of exposure:
  - Inhalation
  - Skin contact
Montelukast Tablet Formulation

Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Montelukast:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 5,000 mg/kg
Acute inhalation toxicity : Remarks: No data available
Acute dermal toxicity : Remarks: No data available

Cellulose:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Montelukast:
Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Montelukast:
Species : Rabbit
Result : Severe irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.
**Components:**

**Montelukast:**

| Remains | Remarks: No data available |

**Germ cell mutagenicity**

Not classified based on available information.

**Components:**

**Montelukast:**

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

| Test Type: In vitro mammalian cell gene mutation test |
| Test system: Chinese hamster fibroblasts |
| Result: negative |

| Test Type: Chromosomal aberration |
| Test system: Chinese hamster ovary cells |
| Result: negative |

| Test Type: Alkaline elution assay |
| Test system: rat hepatocytes |
| Result: negative |

<table>
<thead>
<tr>
<th>Genotoxicity in vivo</th>
<th>Test Type: Chromosomal aberration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mouse</td>
<td></td>
</tr>
<tr>
<td>Cell type: Bone marrow</td>
<td></td>
</tr>
<tr>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td>Result: negative</td>
<td></td>
</tr>
</tbody>
</table>

**Cellulose:**

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

| Test Type: In vitro mammalian cell gene mutation test |
| Result: negative |

<table>
<thead>
<tr>
<th>Genotoxicity in vivo</th>
<th>Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mouse</td>
<td></td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
<td></td>
</tr>
<tr>
<td>Result: negative</td>
<td></td>
</tr>
</tbody>
</table>

**Carcinogenicity**

Not classified based on available information.
Montelukast Tablet Formulation

<table>
<thead>
<tr>
<th>Components:</th>
<th>Montelukast:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species:</td>
<td>Rat</td>
</tr>
<tr>
<td>Application Route:</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time:</td>
<td>2 Years</td>
</tr>
<tr>
<td>Result:</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Components:</th>
<th>Cellulose:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species:</td>
<td>Rat</td>
</tr>
<tr>
<td>Application Route:</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time:</td>
<td>72 weeks</td>
</tr>
<tr>
<td>Result:</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Reproductive toxicity**
Not classified based on available information.

**Components:**

**Montelukast:**

Effects on fertility:
- Test Type: Fertility
  - Species: Rat, male
  - Application Route: Oral
  - Fertility: NOAEL: 800 mg/kg body weight
  - Result: Animal testing did not show any effects on fertility.

- Test Type: Fertility
  - Species: Rat, female
  - Application Route: Oral
  - Fertility: LOAEL: 200 mg/kg body weight
  - Symptoms: Reduced fertility

- Test Type: Fertility
  - Species: Rat, female
  - Application Route: Oral
  - Fertility: NOAEL: 100 mg/kg body weight
  - Symptoms: Reduced fertility

**Cellulose:**

- Test Type: One-generation reproduction toxicity study
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative

- Test Type: Fertility/early embryonic development
Montelukast Tablet Formulation

According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”.

SAFETY DATA SHEET

Montelukast Tablet Formulation

Version 3.0
Revision Date: 09.04.2021
SDS Number: 2097351-00006
Date of last issue: 02.10.2020
Date of first issue: 18.10.2017

Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Montelukast:

Species: Monkey, male and female
NOAEL: 150 - 300 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Remarks: No significant adverse effects were reported

Cellulose:

Species: Rat
NOAEL: >= 9.000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Montelukast:

Skin contact: Remarks: May irritate skin.
Eye contact: Symptoms: Severe irritation
Ingestion: Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhoea, Fever
Montelukast Tablet Formulation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Montelukast:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC: 0.073 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility

NOEC: 0.0816 mg/l
Exposure time: 7 d
Species: Cyprinodon variegatus (sheepshead minnow)
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.23 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Remarks: No toxicity at the limit of solubility
### Cellulose:

**Toxicity to fish**
- LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
- Exposure time: 48 h
- Remarks: Based on data from similar materials

### 12.2 Persistence and degradability

**Components:**

**Montelukast:**
- **Biodegradability**: Result: not rapidly degradable
  - Biodegradation: 0%
  - Exposure time: 28 d
- **Stability in water**: Hydrolysis: 50% (21.7 h)

**Cellulose:**
- **Biodegradability**: Result: Readily biodegradable.

### 12.3 Bioaccumulative potential

**Components:**

**Montelukast:**
- **Partition coefficient: n-octanol/water**: log Pow: > 4.3

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

Not relevant

### 12.6 Other adverse effects

No data available

### SECTION 13: Disposal considerations

#### 13.1 Waste treatment methods

**Product**: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. If not otherwise specified: Dispose of as unused product.

**Contaminated packaging**: Empty containers should be taken to an approved waste handling site for recycling or disposal.
SAFETY DATA SHEET
According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”.

Montelukast Tablet Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.0</td>
<td>09.04.2021</td>
<td>2097351-00006</td>
<td>02.10.2020</td>
<td>18.10.2017</td>
</tr>
</tbody>
</table>

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

- KKDIK (30105 (Bis)) - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex 17): Not applicable
- Regulation on Persistent Organic Pollutants (Number 30595): Not applicable
- Regulation on prevention of major industrial accidents. Reg number 30702: Not applicable

Other regulations:
According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”.
- Regulation on Classification, Labelling and Packaging of Substances and Mixtures. Dated 11 December 2013, Numbered 28848 (Bis) Ministry of Environment and Forestry.
- Regulation on Dust Control (No: 28812, 2013). Occupational Dust Exposure Limit Values (Annex 1)

The components of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined
SAFETY DATA SHEET
According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”.

Montelukast Tablet Formulation

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The SDS has been prepared by: Name: Gökhan Ardıç; Contact email: sds@chemleg.com; Telephone number: +90 216 706 1307; Certificate Number: Lonca KDU 34 / 2020.08; Certificate Date: 22 September 2020; Valid Until: 22 September 2025

Full text of H-Statements

H319 : Causes serious eye irritation.

The Turkish SDS has been prepared according to the Regulation on Safety Data Sheets for Hazardous Substances and Mixtures No. 29204.

Full text of other abbreviations

Eye Irrit. : Eye irritation
TR OEL DU : Turkey. Regulation on Dust Control. Occupational Dust Exposure Limit Values (Annex 1)
TR OEL DU / ZOAD/TWA : Time Weighted Average Value

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA -
SAFETY DATA SHEET

According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”.

Montelukast Tablet Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.0</td>
<td>09.04.2021</td>
<td>2097351-0006</td>
<td>02.10.2020</td>
<td>18.10.2017</td>
</tr>
</tbody>
</table>

Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bio-accumulative

Further information


Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

TR / EN